SCHEMBL266285

SCHEMBL266285

COc1ccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2cccc(F)c2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 1/20 0.59
SLC34A1 Q06495 1/20 0.59
SLC34A3 Q8N130 1/20 0.59
SLC20A1 Q8WUM9 1/20 0.59
RAB9A P51151 4/20 0.58
NPC1 O15118 3/20 0.58
PKM P14618 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
KDM4E B2RXH2 3/20 0.55
OPRK1 P41145 1/20 0.55
HTT P42858 1/20 0.55
MAPT P10636 4/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
USP2 O75604 1/20 0.52
TP53 P04637 1/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CYP1A2 P05177 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266286 1.00 SLC34A2 (0.59) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL265355 0.93 RAB9A (0.58) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL265354 0.93 RAB9A (0.58) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL266198 0.92 NPC1 (0.61) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL266197 0.92 NPC1 (0.61) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL267956 0.90 NPC1 (0.59) RAB9ANPC1PKMSMN1; SMN2TDP1
SCHEMBL267955 0.90 NPC1 (0.59) RAB9ANPC1PKMSMN1; SMN2TDP1
SCHEMBL268848 0.90 RAB9A (0.59) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL268849 0.90 RAB9A (0.59) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL269542 0.90 RAB9A (0.59) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885SLC34A1 4/4885SLC34A3 12/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.